Earlier and more precise palliative care

Microelectronic – Front-End Module (FEM) is sponsored by European Commission — Horizon Europe. Expected Outcome: The targeted outcomes reflect the above challenges and cover a comprehensive Front End module design which: Covers the FR3 range as defined by the relevant Agenda Item of WRC 27 (7 to 15 GHz range) with possible extension up to 24 GHz if required by some regional implementations, with inherent tuning capabilities to accommodate potential regional variations. Mitigates interferences with incumbent FR3 band users and maximises sharing capabilities across the band in line with the European regulatory approach on spectrum sharing. Enables integration of a large number of antenna elements beyond the State of the Art and support massive MIMO implementation with compensation of increased path loss compared to 5G FR1 implementations. Enables at least an order-of-magnitude increase in RF processing compared to 5G FR1 implementations. Enables 5G cell site reuse and minimises deployment complexity on top of 5G sites deployment. Enables low-cost and low energy implementation of the elementary constituent modules, efficient packaging and is mainly based on the integration of microelectronics heterogeneous technologies where European industry has strong expertise and know-how. Addresses new 6G requirements for greater uplink capacity as required by new classes of traffic/use cases. Enables concurrent and efficient implementation of Sub Band Full Duplex (SBFD) and Integrated Sensing and Communications (ISAC), whilst minimising the waveform differences between the communication and the sensing function, with maximisation of common functional blocks as appropriate. Addresses ITU requirements for IMT 2030 especially for what concerns increased carrier rate, user rate and latency. Enables support of both cellular (FR1-like) and FWA (FR2-like) use case scenarios. It is based on a strong and lasting cooperation between European lead suppliers of telecom systems and technologies and lead suppliers of European microelectronics systems and technologies, in view of stimulating a telecom components ecosystem in Europe and to clearly increase European sovereignty in the domain. Is supported by advanced higher TRL design tools, e.g. EDA, PDK. Establishes a clear pathway towards downstream industrialisation in Europe and use of the relevant pilot lines from the Chips JU as a function of the eventual technology selection for implementation (to be covered in the Chips JU call) Contribute to the Apply AI Strategy policy of the Union Objective: Please refer to the "Specific Challenges and Objectives" section for Stream B-02 in the Work Programme, available under ‘Topic Conditions and Documents - Additional Documents’. Scope: The scope of this topic focuses on the following areas: A FEM design that covers the FR3 frequency range, also taking into account the upper part of the 6Ghz band, potentially usable for Mobile Services (6.425- 7.125 GHz). This does not preclude addressing higher sub-bands of the FR3 spectrum to cater for regional regulatory variations and to include ISAC capabilities. The design includes the characterisation and specification of the FEM constituent elements, such as the power amplifiers, LNB, filters, multiplexers/multipliers, ADC and DAC stages, beamformers, and antenna arrays. It also covers the specification of the digital functionalities to be implemented in the FEM, such as DPD, beam steering, channel selection and adaptation as typical examples. This detailed specification part is expected to be subject to tight links with the project selected under the Chips JU Work Programme 2026, as the two projects should complement each other. The design of a complete FEM, including a Digital Front End, a Radio Front End, antenna elements with the needed conversion stages and capable of handling at least 200 MHz channels and compatible with 400 MHz channels. It enables high-throughput/capacity fronthaul with performance capabilities close to those defined by the ITU 2030 Framework (ITU-R Recommendation M.2160-0) for peak data Programme areas: Digital, Industry and Space, Global Challenges and European Industrial Competitiveness, Key Digital Technologies, Horizon Europe (HORIZON) Keywords: Communication engineering and systems telecommunications, 6G, smart networks and services, sns

ERA Fellowships is sponsored by European Commission — Horizon Europe. Expected Outcome: This action builds on the MSCA Postdoctoral Fellowships 2026 action (HORIZON-MSCA-PF-2026). The target group are host organisations located in Widening countries. Project results are expected to contribute to the following outcomes : For supported ERA Fellows: Increased set of research and transferable skills and competences, leading to improved employability and career prospects of fellows within academia and beyond; New mind-sets and approaches to R&I work forged through international, inter-sectoral and interdisciplinary experience; Enhanced networking and communication capacities with scientific peers, as well as with the general public, that will increase and broaden the research and innovation impact; For participating organisations in the Widening countries: Increased alignment of working conditions for researchers in accordance with the principles set out in the European Charter for Researchers [1] ; Enhanced quality and sustainability of research training and supervision; Increased global attractiveness, visibility and reputation; Stronger R&I capacity and output; better transfer of knowledge. For Widening countries: More postdoctoral researchers attracted to Widening countries with competitive grants and attractive working and employment conditions. Scope: Fellowships should be provided to excellent researchers, undertaking cross-border mobility. Applications must be made jointly by the researcher together with a legal entity in the academic or non-academic sector located in a Widening country. ERA Fellowships should take place in a Widening country. Fellowships are open to researchers of any nationality who wish to engage in R&I projects by either coming to the EU from any country in the world or moving within the EU to a Widening country. Secondments Researchers receiving an ERA Fellowship may opt to include a secondment phase, within the overall duration of their fellowship in any country worldwide. The secondment phase can be a single period or be divided into shorter mobility periods. Secondments cannot exceed one third of the standard fellowship duration and should be in line with the project objectives, adding significant value and impact to the fellowship. Placements in the non-academic sector ERA Fellowships can provide an additional period of up to six months to support researchers opting for a placement at the end of the project to work on R&I projects in an organisation from the non-academic sector established in an EU Member State or Horizon Europe Associated Country. While this possibility is also available to fellows recruited in the non-academic sector, such a placement should be implemented at a different non-academic host organisation established in an EU Member State or Horizon Europe Associated Country. The request for such a non-academic placement should be an integral part of the proposal, explaining the added value for the project and for the career development of the researcher, and will be subject to evaluation. This incentive aims at promoting career moves between sectors and organisations and thereby stimulate innovation and knowledge transfer while expanding career opportunities for researchers. Training activities The training activities implemented under the ERA Fellowships should include training for key transferable skills [2] , foster innovation and entrepreneurship, (e.g. commercialisation of results, Intellectual Property Rights, communication, public engagement and citizen science), foster good scientific conduct such as research integrity and promote Open Science practices (open access to publications and to other research outputs, including data, FAIR data management, societal engagement and citizen science, etc.). Career Development Plan In order to equip ERA Fellows with skills that enhance and expand their career opportunities inside and outside academia, a Career Development Plan should be established jointly by the supervisor(s) and the rese Programme areas: Widening participation and spreading excellence, Widening Participation and Strengthening the European Research Area, Horizon Europe (HORIZON)

Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers is sponsored by European Commission — Horizon Europe. Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: Patients with refractory cancers and their caregivers/families will have access to optimised, tailored and affordable immunotherapeutic interventions that increase their quality of life, across European regions, EU Member States and Associated Countries; Healthcare professionals and academia will have access to clinical evidence, on effectiveness of immunotherapeutic interventions, to deploy evidence-based treatment interventions with improved patient selection that improve outcomes in real life, i.e. in routine healthcare, for patients with refractory cancers who often present with co-morbidities; National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries will have the evidence to implement and reimburse optimised and affordable immunotherapeutic interventions in their healthcare systems, including in everyday medical practice. Scope: While cancer research and innovation have generated novel treatment options, patients with refractory cancers across Europe need access to more effective, affordable and tailored cancer immunotherapeutic interventions which keep up with increasing demands in a complex and fragmented oncology healthcare landscape with spiralling healthcare costs. Pragmatic clinical trials focus on choosing between care options. Pragmatic trials evaluate effectiveness of interventions in settings that more closely resemble routine, real-world settings, aiming to produce evidence directly applicable to clinical practice [1] . Proposals should address all the following: Conduct randomised or cluster-randomised academic investigator-initiated [2] pragmatic clinical trials that benefit patients with refractory cancers - at any stage of the disease, for any cancer subtype, in any age group or part of society - to deliver effective, affordable and tailored immunotherapeutic interventions for implementation by healthcare systems at the level of local communities, European regions, EU Member States and Associated Countries. All data should be disaggregated by sex, gender, age and other relevant variables, such as by measures of socio-economic status or ethnicity. Translational research is limited to supporting biomarker-informed patient stratification and the conduct and analyses of the proposed clinical trial(s). The primary and secondary endpoints of the pragmatic clinical trials should target overall survival, patient-reported outcomes and quality of life issues considered important by and for cancer patients and their caregivers/families. Such endpoints should be defined together with patients and their caregivers/families through research that stimulates social innovation and supports end-user engagement using participative research models. The chosen treatment intervention(s) should be adapted to the particular needs of the target population and to the specificities of the provision of care at local, regional, or national level, duly reflecting the diversity across EU Member States and Associated Countries. Furthermore, affordability and accessibility should be taken into account. Applicants should include an appropriate mix of stakeholders from various disciplines, sectors [3] and regional as well as national health authorities, and provide details of the clinical study(ies) in the dedicated annex using the template provided in the submission system. The successful proposals are expected to build on resources made available by the Knowledge Centre on Cancer (KCC) [4] to foster EU alignment and coordination. Successful proposals will be asked to join the 'Diagnosis and Treatment' cluster for the EU Cancer Mission [5] and should include a budget for networking, attendance at meetings, and joint activities [6] . The Commission will facilitate coordination of these activities. [1] Some e Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Health Keywords: Anticancer therapy, Diagnostic tools (e.g. genetic, imaging), Haematology, Medical devices, Paediatrics, Pharmacogenomics, Pharmacology, pharmacogenomics, drug discovery and design, drug therapy, Radiation therapy, Stem cell therapy, Surgery, Clinical Trials, Rare Cancers

Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.

Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.